ValiRx plc (FRA:EAJF)

Market Cap	2.61M -6.1%
Revenue (ttm)	58.07K +418.5%
Net Income	-2.08M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0020
Previous Close	0.0005
Day's Range	0.0020 - 0.0020
52-Week Range	0.0005 - 0.0190
Beta	n/a
RSI	92.75
Earnings Date	Apr 21, 2026

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 14
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EAJF

Financial Performance

In 2024, ValiRx's revenue was 49,775, an increase of 418.49% compared to the previous year's 9,600. Losses were -1.92 million, -5.99% less than in 2023.

Financial numbers in GBP